Last $0.55 USD
Change Today +0.039 / 7.57%
Volume 22.1M
AEMD On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

aethlon medical inc (AEMD) Snapshot

Open
$0.52
Previous Close
$0.52
Day High
$0.63
Day Low
$0.52
52 Week High
11/24/14 - $0.72
52 Week Low
09/18/14 - $0.10
Market Cap
163.7M
Average Volume 10 Days
17.8M
EPS TTM
$-0.04
Shares Outstanding
295.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AETHLON MEDICAL INC (AEMD)

Related News

No related news articles were found.

aethlon medical inc (AEMD) Related Businessweek News

No Related Businessweek News Found

aethlon medical inc (AEMD) Details

Aethlon Medical, Inc. operates as a medical device company, which focuses on creating devices for the treatment of cancer, infectious diseases, and other life-threatening conditions. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The company’s Aethlon Hemopurifier is intended for the treatment of antiviral drug-resistance in hepatitis-C virus and human immunodeficiency virus infected individuals; serves as a countermeasure against viral pathogens not addressed by drug or vaccine therapies; and represents the therapeutic strategy to address cancer promoting exosomes. It also develops exosome-based products to diagnose and monitor cancer, infectious diseases, and neurological disorders; and is developing a medical device to reduce the incidence of sepsis in combat-injured soldiers. The company was formerly known as Bishop Equities Inc and changed its name to Aethlon Medical, Inc. in March 2000. The company was founded in 1991 and is based in San Diego, California.

10 Employees
Last Reported Date: 07/15/14
Founded in 1991

aethlon medical inc (AEMD) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $400.0K
President and Director
Total Annual Compensation: $240.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $183.0K
Chief Scientific Officer, Vice President and ...
Total Annual Compensation: $195.0K
Compensation as of Fiscal Year 2014.

aethlon medical inc (AEMD) Key Developments

Aethlon Medical, Inc. Discloses Expanded Access Emergency Use Pathway to Treat Ebola in the United States

Aethlon Medical, Inc. disclosed that it will provide Hemopurifier(R) therapy under FDA expanded access emergency use provisions to support requests from qualified physicians and institutes that may seek to treat ebola virus infection in the United States. The company previously disclosed that it would provide Hemopurifier(R) therapy on a humanitarian basis through FDA compassionate use access provisions, which allow for the use of an investigational device to treat an individual patient or small group based on clearance by FDA prior to treatment. Based on FDA guidance, the company will now provide Hemopurifier(R) therapy to treat Ebola infection through expanded access emergency use provisions in the United States. Expanded access emergency use of an investigational device does not require advance FDA approval for life threatening circumstances for which an alternative therapy is not available. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans. The Aethlon Hemopurifier(R) is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. In the treatment of Ebola, the company recently announced that Hemopurifier(R) therapy was administered to Ugandan physician, who was infected with Ebola in Sierra Leone where he was treating Ebola patients. At the time of treatment, which occurred at Frankfurt University Hospital in Germany, the patient was unconscious and suffering from multiple organ failure. The patient's viral load prior to the administration of a single 6.5-hour Hemopurifier(R) treatment was measured at 400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load was measured at 1,000 copies/ml and never again rose above that level. The treatment was well tolerated with no adverse events reported. Additionally, a post-treatment elution protocol verified that 242 million Ebola viruses were captured within the Hemopurifier(R) during treatment. Since the administration of Hemopurifier(R) therapy, Frankfurt University Hospital officials have reported that the Ebola virus is no longer detectable in the patient's blood and full recovery is expected. The company will soon begin the first U.S. clinical Hemopurifier(R) studies following the United States Food and Drug Administration's (FDA)'s approval of an Investigational Device Exemption (IDE). The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including Ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).

Aethlon Medical, Inc. Updates on Hemopurifier

Aethlon Medical, Inc. created the Hemopurifier(R), a bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. The Frankfurt University Hospital patient, a Ugandan physician, who was infected with Ebola in Sierra Leone where he was treating Ebola patients, was not administered Hemopurifier(R) therapy until 12 days after being diagnosed. At the time of Hemopurifier(R) administration, Dr. Geiger reported that the Ebola patient was unconscious and suffering from multiple organ failure, which required mechanical ventilation, continuous dialysis and the administration of vasopressor medications. The patient's viral load prior to the administration of a single 6.5-hour Hemopurifier(R) treatment was measured 400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load was measured at 1,000 copies/ml and never again rose above that level. The treatment was well tolerated with no adverse events reported. Since the administration of Hemopurifier(R) therapy, Frankfurt University Hospital officials have reported that Ebola virus is no longer detectable in the patient's blood and full recovery is expected. Aethlon will soon begin the first U.S. clinical Hemopurifier(R) studies following the United States Food and Drug Administration's (FDA)'s approval of an Investigational Device Exemption (IDE). The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including Ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).

Aethlon Medical, Inc. Presents at SeeThruEquity Fall Microcap Investor Conference 2014, Nov-12-2014 10:00 AM

Aethlon Medical, Inc. Presents at SeeThruEquity Fall Microcap Investor Conference 2014, Nov-12-2014 10:00 AM. Venue: Convene Midtown East, New York, New York, United States. Speakers: James A. Joyce, Founder, Chairman, Chief Executive Officer, Principal Accounting Officer and Secretary.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEMD:US $0.55 USD +0.039

AEMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AEMD.
View Industry Companies
 

Industry Analysis

AEMD

Industry Average

Valuation AEMD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 101.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 114.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AETHLON MEDICAL INC, please visit www.aethlonmedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.